PortalPublikationenSecond-Line Treatment in Pancreatic Cancer Patients: Who Pro...

Second-Line Treatment in Pancreatic Cancer Patients: Who Profits?--Results From the CONKO Study Group

Standard

Second-Line Treatment in Pancreatic Cancer Patients: Who Profits?--Results From the CONKO Study Group. / Sinn, Marianne; Dälken, Louise; Striefler, Jana Käthe; Bischoff, Sven; Schweitzer, Nora; Pelzer, Uwe; Dörken, Bernd; Riess, Hanno; Stieler, Jens Maria.

in: PANCREAS, Jahrgang 45, Nr. 4, 04.2016, S. 601-5.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Sinn, M, Dälken, L, Striefler, JK, Bischoff, S, Schweitzer, N, Pelzer, U, Dörken, B, Riess, H & Stieler, JM 2016, 'Second-Line Treatment in Pancreatic Cancer Patients: Who Profits?--Results From the CONKO Study Group', PANCREAS, Jg. 45, Nr. 4, S. 601-5. https://doi.org/10.1097/MPA.0000000000000533

APA

Sinn, M., Dälken, L., Striefler, J. K., Bischoff, S., Schweitzer, N., Pelzer, U., Dörken, B., Riess, H., & Stieler, J. M. (2016). Second-Line Treatment in Pancreatic Cancer Patients: Who Profits?--Results From the CONKO Study Group. PANCREAS, 45(4), 601-5. https://doi.org/10.1097/MPA.0000000000000533

Vancouver

Sinn M, Dälken L, Striefler JK, Bischoff S, Schweitzer N, Pelzer U et al. Second-Line Treatment in Pancreatic Cancer Patients: Who Profits?--Results From the CONKO Study Group. PANCREAS. 2016 Apr;45(4):601-5. https://doi.org/10.1097/MPA.0000000000000533

Bibtex

@article{a1b8c1a90afe4c2491d7f62e966a8e61,
title = "Second-Line Treatment in Pancreatic Cancer Patients: Who Profits?--Results From the CONKO Study Group",
abstract = "OBJECTIVES: With increasing numbers of therapeutic options in inoperable pancreatic cancer (PAC), patients tend to receive more than just a first line (FL) therapy.METHODS: All patients who started FL for PAC at our institution (1997-2012) were retrospectively studied to identify patient's and treatment characteristics. Significant parameters in regard to second-line (SL) related survival were looked for as the basis for a prognostic model. This score was validated in a patient cohort from the CONKO-003 study.RESULTS: Two hundred eighty of 521 (53.7%) patients received SL therapy, median overall survival (OS) from the beginning of SL (OS2) was 5.1 months. Significant more SL patients had undergone surgery, a higher Karnofsky performance state (KPS) and a duration of FL longer than 4 months.Prognostic factors impacting OS2 were KPS, carbohydrate antigen 19-9 levels at start of SL and the duration of FL. These 3 factors establish a prognostic score--validated in CONKO-003--for SL patients with 3 subgroups: {"}good{"} (median OS2, 9.3 months), {"}intermediate{"} (median OS2, 7.1 months), {"}poor{"} prognosis (median OS2, 3.8 months; P < 0.001).CONCLUSIONS: Among patients with PAC, more than 50% receive SL therapy. Our prognostic model identifies 3 subgroups and can identify patients with a maximum benefit of SL therapy.",
keywords = "Adenocarcinoma/drug therapy, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, CA-19-9 Antigen/analysis, Clinical Trials, Phase III as Topic, Female, Humans, Kaplan-Meier Estimate, Karnofsky Performance Status, Male, Middle Aged, Multivariate Analysis, Outcome Assessment, Health Care/methods, Pancreatic Neoplasms/drug therapy, Proportional Hazards Models, Randomized Controlled Trials as Topic, Retrospective Studies",
author = "Marianne Sinn and Louise D{\"a}lken and Striefler, {Jana K{\"a}the} and Sven Bischoff and Nora Schweitzer and Uwe Pelzer and Bernd D{\"o}rken and Hanno Riess and Stieler, {Jens Maria}",
year = "2016",
month = apr,
doi = "10.1097/MPA.0000000000000533",
language = "English",
volume = "45",
pages = "601--5",
journal = "PANCREAS",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

RIS

TY - JOUR

T1 - Second-Line Treatment in Pancreatic Cancer Patients: Who Profits?--Results From the CONKO Study Group

AU - Sinn, Marianne

AU - Dälken, Louise

AU - Striefler, Jana Käthe

AU - Bischoff, Sven

AU - Schweitzer, Nora

AU - Pelzer, Uwe

AU - Dörken, Bernd

AU - Riess, Hanno

AU - Stieler, Jens Maria

PY - 2016/4

Y1 - 2016/4

N2 - OBJECTIVES: With increasing numbers of therapeutic options in inoperable pancreatic cancer (PAC), patients tend to receive more than just a first line (FL) therapy.METHODS: All patients who started FL for PAC at our institution (1997-2012) were retrospectively studied to identify patient's and treatment characteristics. Significant parameters in regard to second-line (SL) related survival were looked for as the basis for a prognostic model. This score was validated in a patient cohort from the CONKO-003 study.RESULTS: Two hundred eighty of 521 (53.7%) patients received SL therapy, median overall survival (OS) from the beginning of SL (OS2) was 5.1 months. Significant more SL patients had undergone surgery, a higher Karnofsky performance state (KPS) and a duration of FL longer than 4 months.Prognostic factors impacting OS2 were KPS, carbohydrate antigen 19-9 levels at start of SL and the duration of FL. These 3 factors establish a prognostic score--validated in CONKO-003--for SL patients with 3 subgroups: "good" (median OS2, 9.3 months), "intermediate" (median OS2, 7.1 months), "poor" prognosis (median OS2, 3.8 months; P < 0.001).CONCLUSIONS: Among patients with PAC, more than 50% receive SL therapy. Our prognostic model identifies 3 subgroups and can identify patients with a maximum benefit of SL therapy.

AB - OBJECTIVES: With increasing numbers of therapeutic options in inoperable pancreatic cancer (PAC), patients tend to receive more than just a first line (FL) therapy.METHODS: All patients who started FL for PAC at our institution (1997-2012) were retrospectively studied to identify patient's and treatment characteristics. Significant parameters in regard to second-line (SL) related survival were looked for as the basis for a prognostic model. This score was validated in a patient cohort from the CONKO-003 study.RESULTS: Two hundred eighty of 521 (53.7%) patients received SL therapy, median overall survival (OS) from the beginning of SL (OS2) was 5.1 months. Significant more SL patients had undergone surgery, a higher Karnofsky performance state (KPS) and a duration of FL longer than 4 months.Prognostic factors impacting OS2 were KPS, carbohydrate antigen 19-9 levels at start of SL and the duration of FL. These 3 factors establish a prognostic score--validated in CONKO-003--for SL patients with 3 subgroups: "good" (median OS2, 9.3 months), "intermediate" (median OS2, 7.1 months), "poor" prognosis (median OS2, 3.8 months; P < 0.001).CONCLUSIONS: Among patients with PAC, more than 50% receive SL therapy. Our prognostic model identifies 3 subgroups and can identify patients with a maximum benefit of SL therapy.

KW - Adenocarcinoma/drug therapy

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - CA-19-9 Antigen/analysis

KW - Clinical Trials, Phase III as Topic

KW - Female

KW - Humans

KW - Kaplan-Meier Estimate

KW - Karnofsky Performance Status

KW - Male

KW - Middle Aged

KW - Multivariate Analysis

KW - Outcome Assessment, Health Care/methods

KW - Pancreatic Neoplasms/drug therapy

KW - Proportional Hazards Models

KW - Randomized Controlled Trials as Topic

KW - Retrospective Studies

U2 - 10.1097/MPA.0000000000000533

DO - 10.1097/MPA.0000000000000533

M3 - SCORING: Journal article

C2 - 26646276

VL - 45

SP - 601

EP - 605

JO - PANCREAS

JF - PANCREAS

SN - 0885-3177

IS - 4

ER -